Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 32%
Hold 14%
Sell 5%
Strong Sell 9%

Bulls say

Arcturus Therapeutics Holdings Inc. is poised for significant growth, driven by the anticipated clinical data readouts of its proprietary mRNA development programs in 2025, which could lead to substantial appreciation in its stock value if results are favorable. The company's revenue projection of over $500 million five years post-launch highlights its potential in the market, supported by the recent European Commission marketing authorization for its COVID-19 vaccine, Kostaive, which adds to its growing portfolio. Furthermore, the collaboration with CSL Seqirus to commercialize Kostaive reduces execution risk, enhancing the company's prospects as it expands its manufacturing capabilities in Japan.

Bears say

The financial outlook for Arcturus Therapeutics Holdings Inc. is negative due to significant revisions in revenue estimates for its COVID-19 product, Kostaive, which has been downgraded from $156.4 million to $11.8 million for the 2026 fiscal year, following lower-than-expected vaccination projections. Additionally, the company reported a net loss of $30 million for the fourth quarter of 2024, indicating ongoing operational challenges, despite holding approximately $294 million in cash and equivalents. The analysis is further hindered by several high-risk factors, including potential safety concerns related to its mRNA drugs, the possibility of unsuccessful clinical trials, and risks associated with regulatory approvals, which collectively weigh heavily on investor confidence.

Arcturus Therapeutics (ARCT) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 32% recommend Buy, 14% suggest Holding, 5% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 22 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.